信立泰：SAL0145药品临床试验申请获得受理

Core Viewpoint - The company has received acceptance for the clinical trial application of its innovative drug SAL0145 injection, which is developed with proprietary intellectual property and is intended for the treatment of MASH [1] Group 1 - The drug SAL0145 is a siRNA medication developed by the company [1] - The clinical trial application submitted is specifically for the treatment of MASH [1]